Russia Registers Domestic Radium-223 Drug 'Rakurs' for Prostate Cancer Treatment

Key Insights

• Russia's Federal Medical and Biological Agency (FMBA) has registered Rakurs (223Ra), a domestic radiopharmaceutical, for treating prostate cancer.
• Rakurs (223Ra) simultaneously targets metastases and alleviates pain, potentially reducing the need for additional pain medications.
• The registration of this import-substituted drug aims to improve the availability and reduce logistical delays in accessing this treatment for Russian citizens.

Russia's Federal Medical and Biological Agency (FMBA) has announced the registration of Rakurs (223Ra), a domestically produced radiopharmaceutical drug indicated for the treatment of prostate cancer. This development aims to enhance the availability of this treatment option for Russian patients while reducing logistical challenges.

Rakurs (223Ra) is designed to target cancer metastases while also providing pain relief, potentially decreasing the reliance on supplementary pain management medications. The FMBA emphasized that the registration of this import-substituted drug is a significant step towards ensuring a more consistent and accessible supply of this treatment modality for Russian citizens.

In related news, Russia is planning to initiate the first phase of clinical trials for a novel cancer vaccine. The initial trial will involve 50 cancer patients.